LAS17 Antibody

What is Las17 and why is it important in yeast cell biology?

Las17 (also known as Bee1p) is the Saccharomyces cerevisiae homologue of the human Wiskott-Aldrich Syndrome protein (WASP). It serves as the strongest activator of the Arp2/3 complex in yeast cells, making it a critical component for actin polymerization and cytoskeletal organization. Las17 is essential for actin patch assembly, which affects multiple cellular processes including endocytosis, budding, and cytokinesis. The protein is proline-rich and localizes to cortical patches independently of polymerized actin, where it facilitates the polarized localization of the Arp2/3 complex. Las17-deficient cells exhibit severe defects in receptor-mediated endocytosis and abnormal actin aggregation in buds, highlighting its importance in maintaining normal cellular architecture and function .

What types of Las17 antibodies are available for research applications?

Research-grade antibodies against Las17 have been successfully developed by raising affinity-purified polyclonal antibodies against recombinant Las17 amino- and carboxy-terminal fragments. These are commonly referred to as Las-A and Las-B antibodies, respectively. Both antibodies recognize bands of expected molecular weight (approximately 67.7 kDa) in Saccharomyces cerevisiae cytosolic extracts, with their specificity confirmed using cytosolic extracts from cells carrying a deletion of the LAS17 gene (las17Δ). While both antibodies work well for immunoblotting, the Las-A antibody has demonstrated particular efficacy for immunoprecipitation of endogenous Las17 from yeast cell extracts .

How can I validate the specificity of Las17 antibodies?

Validating Las17 antibody specificity requires several complementary approaches:

• Genetic validation: Compare immunoblotting results between wild-type and las17Δ yeast strains. A specific antibody will show a band at the expected molecular weight (67.7 kDa) in wild-type extracts that is absent in las17Δ extracts.

• Multiple antibody confirmation: Use both N-terminal (Las-A) and C-terminal (Las-B) targeting antibodies. Specific Las17 bands should be detected by both antibodies, while nonspecific cross-reactive bands will typically be detected by only one antibody and often at molecular weights far from the expected 67.7 kDa.

• Functional validation: Confirm the antibody's ability to immunoprecipitate Las17 and co-precipitate known interacting partners such as Sla1 and components of the Arp2/3 complex.

• Controls for cross-reactivity: Include appropriate negative controls in immunoprecipitation experiments to exclude nonspecific binding .

What are the optimal conditions for using Las17 antibodies in immunoprecipitation experiments?

For effective immunoprecipitation of Las17 from yeast extracts, the following methodological approach is recommended:

• Extract preparation: Prepare detergent-free cytosolic extracts by removing membrane fractions through ultracentrifugation. This approach isolates cytosolic Las17 and preserves protein complexes.

• Antibody selection: The Las-A antibody (targeting the N-terminal fragment) demonstrates superior performance for immunoprecipitation compared to Las-B.

• Co-immunoprecipitation detection: When investigating Las17 protein interactions, immunoprecipitate using Las-A antibody and probe for interacting partners (e.g., Sla1) by immunoblotting, or vice versa.

• Negative controls: Include control immunoprecipitations with non-specific antibodies to confirm specificity of detected interactions.

Research has shown this approach successfully detects the Las17-Sla1 complex in both membrane-bound and cytosolic fractions, indicating their stable association in multiple cellular compartments .

How can I use Las17 antibodies to study protein complexes by size-exclusion chromatography?

Size-exclusion chromatography combined with immunoblotting provides valuable insights into the native size and composition of Las17-containing complexes:

• Sample preparation: Fractionate yeast cytosolic extracts by size-exclusion chromatography.

• Fraction analysis: Analyze each fraction by immunoblotting with Las17 antibodies and antibodies against potential interacting partners (e.g., Sla1, End3).

• Complex identification: Las17 co-fractionates with Sla1 but not with End3, suggesting a specific stable complex.

• Validation by immunoprecipitation: Subject size-exclusion fractions to immunoprecipitation with Las-A antibody followed by immunoblotting to confirm the presence of both Las17 and its interacting partners in the same complex.

• Mutant analysis: Compare fractionation profiles between wild-type and deletion strains (e.g., sla1Δ or las17Δ) to assess complex dependencies.

This approach has revealed that Las17 and Sla1 form a stable complex with a large Stokes radius (eluting around 10 ml in standard columns), and that in the absence of either protein, the elution profile of the remaining protein shifts dramatically (to approximately 17 ml for Las17 in sla1Δ cells and 16.5 ml for Sla1 in las17Δ cells) .

What techniques can be used with Las17 antibodies to study its role in endocytosis?

Multiple complementary techniques utilizing Las17 antibodies can elucidate its role in endocytosis:

• Immunofluorescence microscopy: Use Las17 antibodies to visualize endocytic patch localization in fixed cells, particularly in conjunction with markers for different endocytic stages.

• Biochemical fractionation: Separate membrane and cytosolic fractions followed by immunoblotting to quantify Las17 distribution.

• Immunoprecipitation of endocytic complexes: Precipitate Las17 from cell lysates to identify associated endocytic proteins that may vary during different stages of endocytosis.

• Comparative analysis in endocytic mutants: Apply Las17 antibodies to characterize protein interactions and localization in strains with mutations in endocytic genes.

• Receptor-mediated endocytosis assays: Measure α-factor internalization by the Ste2 receptor in conjunction with Las17 immunoprecipitation to correlate endocytic activity with Las17 complex formation.

Studies have shown that Las17-deficient cells exhibit severe defects in receptor-mediated endocytosis, demonstrating its critical function in this process .

How can Las17 antibodies help characterize the Las17-Sla1 interaction mechanism?

Las17 antibodies have been instrumental in elucidating the complex regulatory mechanism between Las17 and Sla1:

• Direct interaction verification: Immunoprecipitation with Las17 antibodies followed by Sla1 detection (and vice versa) confirms their physical association in vivo.

• Complex stability assessment: Size-exclusion chromatography combined with immunoblotting and immunoprecipitation demonstrates that Las17 and Sla1 form a large, biochemically stable complex in the cytosol.

• Interaction domain mapping: Using Las17 antibodies in pulldown assays with recombinant Las17 fragments helps identify that the interaction occurs through novel Las17 polyproline motifs that are simultaneously class I and class II.

• Functional consequence analysis: Immunoprecipitation of Las17 mutants with altered polyproline motifs can assess how these mutations affect Sla1 binding and subsequent actin regulatory functions.

This approach has revealed that Sla1 inhibits Las17's nucleation-promoting factor (NPF) activity through direct competition with G-actin for binding to Las17's polyproline motifs, providing a molecular mechanism for temporal regulation of actin polymerization during endocytosis .

What methods combine Las17 antibodies with live-cell imaging to study endocytic dynamics?

Researchers can integrate antibody-based biochemical approaches with live-cell imaging through several strategies:

• Correlation of biochemical states with cellular events: Immunoprecipitate Las17 from cells fixed at different timepoints during endocytosis (identified by live imaging) to determine how complex composition changes temporally.

• Validation of GFP-tagged constructs: Confirm that GFP-tagged Las17 behaves similarly to endogenous Las17 by comparing immunoprecipitation results between tagged and untagged strains.

• Analysis of mutant phenotypes: Compare biochemical interaction data from Las17 antibody experiments with live-cell dynamics of Las17-GFP and its binding partners like Sla1-RFP or Abp1-RFP.

• Temporal mapping of interactions: Correlate the timing of Las17-Sla1 dissociation (detected biochemically) with actin polymerization events (observed in live cells).

Live-cell imaging has shown that wild-type Las17-GFP and Sla1-RFP arrive at endocytic sites simultaneously with indistinguishable lifetimes, whereas Las17 mutants defective in Sla1 binding show altered recruitment patterns, arriving approximately 18 seconds after Sla1 .

How do Las17 polyproline motifs affect experimental detection and functional outcomes?

The polyproline motifs in Las17 significantly impact both experimental detection and protein function:

These findings demonstrate that when using Las17 antibodies to study protein interactions, researchers must consider how mutations in polyproline motifs might affect detection outcomes. Additionally, these motifs play crucial roles in:

• Mediating the Las17-Sla1 interaction

• Regulating actin polymerization through competition between Sla1 and G-actin

• Controlling the timing of actin assembly at endocytic sites

Understanding these relationships is essential for interpreting experimental results when using Las17 antibodies in research applications .

What are common issues when using Las17 antibodies and how can they be resolved?

When working with Las17 antibodies, researchers may encounter several challenges:

• Nonspecific bands in immunoblotting: Both Las-A and Las-B antibodies cross-react with unrelated proteins. Mitigation strategies include:

  • Using las17Δ extracts as negative controls

  • Confirming specific bands by detection with both antibodies

  • Focusing on bands at the expected molecular weight (67.7 kDa)

  • Optimizing blocking and washing conditions

• Variable immunoprecipitation efficiency: Las17 interactions may be sensitive to experimental conditions. Improvements can be achieved by:

  • Using the Las-A antibody, which shows superior immunoprecipitation performance

  • Preparing detergent-free cytosolic extracts for studying stable interactions

  • Optimizing salt concentration to preserve specific complexes

  • Cross-validation with reciprocal immunoprecipitations (using antibodies against interacting partners)

• Detection of Las17 mutants: Point mutations in polyproline motifs might affect antibody recognition. Researchers should:

  • Verify antibody recognition by immunoblotting total cell extracts

  • Assess whether changes in immunoprecipitation efficiency reflect altered interactions or detection issues

  • Use multiple antibodies targeting different regions of Las17

How can I optimize immunofluorescence protocols for detecting endogenous Las17?

Optimizing immunofluorescence protocols for Las17 detection requires careful consideration of several factors:

• Fixation method: Aldehyde-based fixatives may preserve Las17 localization better than methanol, which can disrupt actin structures.

• Antibody selection and concentration: The Las-A antibody may provide more specific staining. Titrate antibody concentrations to optimize signal-to-noise ratio.

• Spheroplasting conditions: Gentle spheroplasting preserves cortical structures where Las17 localizes. Optimize zymolyase concentration and incubation times.

• Permeabilization: Detergent concentration affects antibody accessibility while potentially disrupting membrane structures. Test different detergents (Triton X-100, saponin) and concentrations.

• Blocking conditions: Extended blocking (3-5 hours) with BSA or normal serum from the secondary antibody host species reduces background.

• Validation approaches:

  • Compare staining patterns with GFP-tagged Las17 in live cells

  • Use las17Δ cells as negative controls

  • Co-stain with markers of known Las17 localization (actin patches, Sla1)

  • Perform peptide competition assays to confirm specificity

Las17 localizes to cortical patches independently of polymerized actin, so co-staining with actin markers can provide valuable contextual information about patch identity and function .

How can Las17 antibodies be used to analyze endocytic defects in yeast mutants?

Las17 antibodies provide powerful tools for characterizing endocytic defects in various yeast mutants:

• Protein expression analysis: Immunoblotting with Las17 antibodies can determine whether endocytic defects in mutant strains correlate with altered Las17 expression levels.

• Complex formation assessment: Immunoprecipitation followed by immunoblotting for interacting partners reveals how mutations affect Las17 complex formation. For example, size-exclusion chromatography has shown that Las17 in sla1Δ cells exhibits a dramatically smaller Stokes radius (eluting at ~17 ml versus ~10 ml in wild-type cells).

• Localization studies: Immunofluorescence using Las17 antibodies can determine whether mutations alter Las17 recruitment to endocytic sites. This approach complements studies with fluorescently tagged proteins, which might not always behave identically to endogenous proteins.

• Synthetic genetic interactions: Las17 antibodies can help characterize protein interactions in strains with temperature-sensitive mutations in genes like ARP2 and ARP3, which show synthetic lethality with las17Δ mutations.

Such applications have revealed that Las17 is required for polarized localization of Arp2/3 and actin, and that Las17-deficient cells show severe defects in receptor-mediated internalization of α-factor by the Ste2 receptor .

What insights can Las17 antibodies provide about the temporal regulation of endocytosis?

Las17 antibodies have contributed significant insights into the temporal regulation of endocytosis through several experimental approaches:

• Temporal protein complex analysis: By immunoprecipitating Las17 at different time points during endocytosis, researchers have identified how protein complexes change over time.

• Correlation with live-cell imaging: Biochemical data from Las17 immunoprecipitation experiments can be correlated with the timing of events observed in live-cell imaging. For instance, wild-type Las17-GFP and Sla1-RFP arrive simultaneously at endocytic sites, but when the Las17-Sla1 interaction is disrupted, this coordination is lost.

• Regulatory mechanism elucidation: Immunoprecipitation studies have revealed that Las17 is kept inactive for approximately 20 seconds after arrival at endocytic sites through its association with Sla1, which inhibits its NPF activity.

• Actin polymerization timing: Las17 antibodies have helped establish that Sla1 inhibits Las17 activity by competing with G-actin for binding to Las17's polyproline motifs, thus restricting actin polymerization to late stages of endocytosis.

These studies have demonstrated that the Las17-Sla1 interaction provides a mechanism for temporal regulation of actin polymerization, ensuring it occurs at the appropriate time during endocytic vesicle formation .

How do Las17 antibodies compare with other tools for studying the actin cytoskeleton?

Las17 antibodies offer distinct advantages and limitations compared to other cytoskeletal research tools:

• Compared to actin antibodies: Las17 antibodies detect specifically endocytic sites, whereas actin antibodies label all actin structures (cables, patches, rings). Las17 arrives at endocytic sites before actin polymerization begins, allowing visualization of early endocytic events.

• Compared to Arp2/3 complex antibodies: Las17 antibodies detect the activator of the complex, providing information about the regulatory state rather than just the presence of the actin nucleation machinery. Las17 is required for polarized localization of Arp2/3.

• Compared to fluorescent protein fusions: Las17 antibodies detect endogenous protein without potential artifacts from tagging, though they cannot be used in live cells. Studies show GFP-tagged Las17 has slightly different dynamics than untagged Las17 detected by antibodies.

• Complementarity with other endocytic markers: Las17 antibodies can be used alongside antibodies against proteins like Sla1 (arrives simultaneously with Las17) and Abp1 (arrives 19 seconds after Las17) to dissect the temporal stages of endocytosis.

Research using these various tools has established that Las17 is the strongest activator of the Arp2/3 complex in yeast cells and that it interacts with multiple proteins including actin, verprolin, Rvs167p, and several SH3 domain proteins .

What experimental designs can distinguish between Las17's role in different cellular processes?

Las17 functions in multiple cellular processes, and carefully designed experiments using Las17 antibodies can differentiate between these roles:

• Endocytosis versus actin patch formation:

  • Receptor-mediated endocytosis assays (e.g., α-factor internalization) combined with Las17 immunoprecipitation

  • Comparative analysis of actin patch morphology versus endocytic efficiency in Las17 mutants

  • Isolation of separate genetic suppressors that rescue different phenotypes

• Cell polarity versus endocytic functions:

  • Assessment of bud site selection patterns in Las17 mutants using bipolar budding assays

  • Correlation of Las17 complex composition with polarized growth versus endocytosis

  • Analysis of genetic interactions between Las17 and polarity-specific versus endocytosis-specific genes

• Direct versus indirect effects on the Arp2/3 complex:

  • In vitro actin polymerization assays with purified components

  • Co-immunoprecipitation of Las17 with Arp2/3 complex in different mutant backgrounds

  • Analysis of synthetic lethal interactions with Arp2/3 complex mutants

Research has demonstrated that Las17 plays distinct roles in receptor-mediated internalization, bipolar bud site selection, and actin patch assembly, with las17Δ cells showing defects in all these processes .

What emerging techniques could enhance the utility of Las17 antibodies in research?

Several emerging techniques promise to expand the research applications of Las17 antibodies:

• Proximity labeling methods: Combining Las17 antibodies with BioID or APEX2 proximity labeling could identify transient or weak interactors in the Las17 interactome that may be missed by conventional immunoprecipitation.

• Super-resolution microscopy: Las17 antibodies optimized for super-resolution techniques like STORM or PALM could reveal nanoscale organization of endocytic sites beyond the diffraction limit of conventional microscopy.

• Mass spectrometry-based interaction proteomics: Quantitative proteomics of Las17 immunoprecipitates from cells at different stages of endocytosis could provide a comprehensive view of dynamic interaction networks.

• Single-molecule tracking: Combining Las17 antibody fragments with quantum dots could enable single-molecule tracking to analyze the dynamics of individual Las17 molecules during endocytosis.

• Cryo-electron microscopy: Las17 antibodies could facilitate structural studies of the Las17-Sla1 complex and its interaction with the Arp2/3 complex and actin, providing molecular insights into regulation mechanisms.

These approaches could address outstanding questions about the molecular mechanisms by which Las17 coordinates with the Arp2/3 complex and other proteins during endocytosis, as well as its role in integrating signals from different regulatory cascades .

How might comparative studies between Las17 and human WASP inform therapeutic approaches?

Comparative studies between yeast Las17 and human WASP using Las17 antibodies could inform therapeutic strategies for Wiskott-Aldrich Syndrome and related disorders:

• Conservation of regulatory mechanisms: Analysis of whether the Las17-Sla1 inhibitory mechanism is conserved in human WASP regulation could identify new therapeutic targets.

• Functional complementation studies: Determining whether human WASP can rescue las17Δ phenotypes, and if so, which domains are required, could reveal functionally critical regions.

• Mutation effects on protein interactions: Comparing how disease-associated WASP mutations affect protein interactions in both yeast and human systems might identify common pathological mechanisms.

• Drug screening platforms: Yeast-based assays using Las17 antibodies could provide high-throughput screening systems for compounds that modulate WASP function or interactions.

• Cytoskeletal dynamics comparison: Quantitative analysis of cytoskeletal defects in Las17 mutants versus WASP-deficient cells could reveal conserved versus divergent functions.

Research has already established that Las17/Bee1p shows homology to human WASP, mutations in which cause severe immunodeficiency (Wiskott-Aldrich Syndrome). WAS patients exhibit cytoskeletal abnormalities of lymphocytes and platelets that may share mechanisms with the actin defects observed in las17Δ yeast cells .

What are the best practices for using Las17 antibodies in yeast cytoskeletal research?

Based on published research, the following best practices are recommended for optimal use of Las17 antibodies:

• Antibody selection: Use Las-A (N-terminal) antibody for immunoprecipitation and Las-A or Las-B for immunoblotting, with appropriate controls to identify specific bands.

• Extract preparation: For studying stable complexes, prepare detergent-free cytosolic extracts by ultracentrifugation rather than using total cell lysates with detergents.

• Validation standards: Always validate specificity using las17Δ strains as negative controls and confirm interactions through reciprocal immunoprecipitations.

• Complementary approaches: Combine antibody-based biochemical methods with genetic approaches and live-cell imaging for comprehensive analysis.

• Context consideration: When interpreting results, consider that Las17 forms a stable complex with Sla1, and mutations affecting this interaction can alter Las17 localization and function.

• Quantification: Quantify immunoblot signals and immunofluorescence intensities relative to appropriate controls for reliable comparisons between experimental conditions.

These best practices have enabled researchers to discover that Las17 is part of a biochemically stable complex with Sla1, that this interaction inhibits Las17's NPF activity through competition with G-actin, and that the complex is important for normal Las17 recruitment to endocytic sites and efficient endocytosis .

What are the critical controls needed when using Las17 antibodies in different experimental contexts?

Different experimental applications of Las17 antibodies require specific controls to ensure reliable and interpretable results:

• For immunoblotting:

  • Extracts from las17Δ strains to identify specific bands

  • Comparison of detection with both Las-A and Las-B antibodies

  • Loading controls (e.g., GAPDH) for quantitative comparisons

  • Purified recombinant Las17 as a positive control

• For immunoprecipitation:

  • Non-specific antibody of the same isotype as negative control

  • Pre-clearing of lysates to reduce nonspecific binding

  • Analysis of unbound fraction to assess precipitation efficiency

  • Reciprocal immunoprecipitation with antibodies against interacting partners

• For immunofluorescence:

  • las17Δ cells as negative controls

  • Peptide competition assays to confirm specificity

  • Secondary antibody-only controls to assess background

  • Co-staining with markers of established localization patterns

• For functional studies:

  • Wild-type Las17 as a positive control for activity assays

  • Analysis of Las17 mutants with altered activity but intact antibody recognition

  • Time-course experiments to establish normal dynamics

  • Comparison with complementary approaches (e.g., GFP-tagged Las17)